



Correction: Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management

Ozgur Mete¹ · Andrée Boucher² · Kasmintan A. Schrader³ · Omar Abdel-Rahman⁴ · Houda Bahig⁵ · Cheryl Ho⁶ · Olfat Kamel Hasan⁷ · Bernard Lemieux⁸ · Eric Winqvist⁹ · Ralph Wong¹⁰ · Jonn Wu¹¹ · Nicole Chau⁶ · Shereen Ezzat¹²

Published online: 6 December 2024
© The Author(s) 2024

Correction: Endocrine Pathology

<https://doi.org/10.1007/s12022-024-09836-x>

In this article, the citation of Table 1 in the first paragraph of section "Constitutional (Germline) Testing in Patients Diagnosed with Non-Anaplastic Follicular Cell-Derived Thyroid Cancer" should have been Table 2. The sentence should read "Constitutional testing is also necessary for those with syndromic manifestations suspicious for other hereditary cancer syndromes not included above or in Table 2 [9, 32, 60, 61] (Fig. 2)."

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License,

which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s12022-024-09836-x>.

Extended author information available on the last page of the article

Authors and Affiliations

Ozgur Mete¹  · Andrée Boucher²  · Kasmintan A. Schrader³  · Omar Abdel-Rahman⁴  · Houda Bahig⁵  · Cheryl Ho⁶  · Olfat Kamel Hasan⁷  · Bernard Lemieux⁸  · Eric Winquist⁹  · Ralph Wong¹⁰ · Jonn Wu¹¹  · Nicole Chau⁶  · Shereen Ezzat¹² 

✉ Ozgur Mete
ozgur.mete2@uhn.ca

Andrée Boucher
andree.boucher@umontreal.ca

Kasmintan A. Schrader
ischrader@bccancer.bc.ca

Omar Abdel-Rahman
Omar.abdelsalam@ahs.ca

Houda Bahig
houda.bahig.med@ssss.gouv.qc.ca

Cheryl Ho
cho@bccancer.bc.ca

Olfat Kamel Hasan
kamelhasan@hhsc.ca

Bernard Lemieux
Bernard.lemieux.med@ssss.gouv.qc.ca

Eric Winquist
eric.winquist@lhsc.on.ca

Ralph Wong
wong2@cancercare.mb.ca

Jonn Wu
jonnwu@bccancer.bc.ca

Nicole Chau
nicole.chau1@bccancer.bc.ca

Shereen Ezzat
shereen.ezzat@uhn.ca

- ¹ Department of Pathology, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Ontario M5G 2C4, Canada
- ² Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
- ³ Hereditary Cancer Program, BC Cancer, Vancouver, British Columbia, Canada
- ⁴ Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
- ⁵ Department of Radiation Oncology, Centre Hospitalier de L'Université de Montréal, Montreal, Quebec, Canada
- ⁶ Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada
- ⁷ Department of Medicine and Department of Medical Imaging, McMaster University, Hamilton, Ontario, Canada
- ⁸ Department of Internal Medicine, Centre Hospitalier Université de Montreal, Montreal, Quebec, Canada
- ⁹ Department of Oncology, Western University, London, Ontario, Canada
- ¹⁰ Department of Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, Canada
- ¹¹ Department of Radiation Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
- ¹² Endocrine Oncology Site Group, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada